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Background: Prevention of infectious diseases is of high priority in the rapidly aging 
population. Unfortunately, vaccine responses in the elderly are frequently diminished. 
Timely vaccination of middle-aged adults might improve the immune responses to vac-
cines, although knowledge on pathogen-specific immune responses and factors affect-
ing these responses, in middle-aged adults is currently limited. We thus investigated the 
immune responses after vaccination with Zostavax consisting of live-attenuated varicella 
zoster virus (VZV).
Methods: Blood samples were taken pre-, 14 days, 28 days, and 1 year after a primary 
VZV vaccination (Zostavax) at middle age (N = 53, 50–65 years of age). VZV-specific 
IFNγ-producing cells were measured by ELISpot, activated T-cells by flow cytometry, 
antibody levels and cytokine responses by fluorescent bead-based multiplex immuno-
assays, and whole blood cellular kinetics by TruCOUNT analysis.
results: Robust short-term enhancement of the VZV-specific IFNγ-producing cell 
numbers was observed post-vaccination in the middle-aged adults. Remarkably, long-
term enhancement of VZV-specific IFNγ-producing cell numbers was induced only in 
participants with low numbers of VZV-specific pre-vaccination IFNγ-producing cells, who 
were significantly older. These participants also showed enhancement of VZV-specific 
activated CD4 T-cells, contrary to “exhausted” VZV-specific CD8 T-cells in participants 
with high numbers of VZV-specific pre-vaccination IFNγ-producing cells. Finally, a high 
CD4/CD8 T-cell ratio was associated with low numbers of pre-vaccination VZV-specific 
IFNγ-producing cells.
conclusion: These results suggest that adults in their early sixties, who showed a high 
CD4/CD8 T-cell ratio and low numbers of VZV-specific IFNγ-producing cells, benefit 
from VZV vaccination. This provides important knowledge on factors affecting VZV-
specific immune responses in middle-aged adults as well as for strategies to strengthen 
immunity before reaching old age.
Keywords: middle-aged adults, varicella zoster virus, T-cells, vaccination, cytokines, preexisting immunity
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inTrODUcTiOn
Prevention of infectious diseases in the elderly is of high prior-
ity to establish healthy aging in the rapidly aging population. 
Unfortunately, vaccine effectivity in the elderly is low, leaving 
part of the elderly vulnerable for infections. Vaccination of 
middle-aged adults, before reaching old age, may be an alterna-
tive option to strengthen the memory immunity of the elderly. 
Currently, knowledge on pathogen-specific immune responses in 
middle-aged adults and factors affecting these immune responses 
is limited.
Herpes zoster is an infectious disease with a large disease 
burden in the elderly. Yearly, approximately 3–5/1,000 persons 
develop herpes zoster, also known as Shingles, of which the vast 
majority is of elderly age (1). Herpes zoster is caused by reactiva-
tion of the latent varicella zoster virus (VZV), causing chickenpox 
after the first encounter during childhood (2). The disease is char-
acterized by painful rashes, mostly located at a single dermatome, 
which may develop into long-lasting complications such as post 
herpetic neuralgia (2, 3). Advancing age and immune suppres-
sion are known as the strongest risk factors for herpes zoster, 
with a sharp increase in cases seen after the age of 50 (3–5). Due 
to rapid aging of the world population, the incidence of herpes 
zoster is likely to increase (1, 6–8). Consequently, understanding 
the VZV-specific immune responses and factors affecting this 
immunity is crucial to decrease the herpes zoster disease burden.
Varicella zoster virus-specific cell-mediated immunity (CMI) 
is essential in the protection against virus reactivation (9). 
Particularly, VZV-specific IFNγ-producing T-cells are seen as 
the best surrogate marker for protection against herpes zoster, 
although the exact number of protective cells remains to be 
established (10, 11). A decline in VZV-specific CMI with age has 
been linked to increased susceptibility to virus reactivation and 
subsequent herpes zoster disease (12–15). By contrast, the role of 
VZV-specific antibodies in the protection against herpes zoster 
is controversial, because contrary to CMI, VZV-specific antibody 
concentrations do not decrease with advancing age (13, 16). 
Nevertheless, some studies suggest a positive correlation between 
antibody levels and protection against herpes zoster (10, 17).
In 2006, a live-attenuated vaccine, Zostavax, was licensed to 
prevent herpes zoster disease in persons of 50 years and older (18). 
However, due to immunological aging, vaccine efficacy strongly 
decreases with advancing age (10, 12, 19). The low vaccine efficacy 
at old (>65 years) age is one of the main reasons for a fierce debate 
about the implementation of the Zostavax vaccine in national 
vaccination programs. Consequently, solutions are warranted to 
decrease the herpes zoster disease burden in the elderly. Currently, 
a herpes zoster subunit vaccine containing VZV glycoprotein E 
and the AS01B adjuvant system is under regulatory evaluation after 
showing promising results in prevention of herpes zoster in the 
elderly (20–22). Yet, knowledge on factors influencing vaccine-
induced VZV-specific immune responses during aging is lacking.
To improve our understanding of VZV-specific immune 
responses, we investigated the cellular and humoral immune 
responses after VZV (Zostavax) vaccination in middle-aged adults 
(50–65 years of age), an interesting target group for harnessing 
memory immunity before reaching old age. Moreover, we studied 
factors associated with vaccine immunogenicity in these middle-
aged adults to be able to better predict the vaccine responses.
MaTerials anD MeThODs
study Design and Participants
Fifty-three middle-aged adults (50–65 years of age) were included 
in this phase IV single-center and open-label study. Participants 
were recruited from an urban area in the middle of the Netherlands 
in March 2015. Potential participants were excluded based on 
the following criteria: antibiotic use or fever (>38°C) within 
the last 14 days, diseases demanding immune suppressive treat-
ment within the last 3 months, a known or suspected immune 
deficiency, a blood coagulation disorder, a neurologic disorder, 
administration of blood products in the past 6 months, serious 
surgery within the last 3  months, the use of hormone supple-
mentation, a suspected allergy toward the vaccine components, 
a history of serious adverse events after previous vaccinations, 
a previous varicella zoster episode, a previous Zostavax vac-
cination, and any vaccination in the month before enrollment. 
Written informed consent was obtained from all participants 
before the study. All procedures were in accordance with the 
Declaration of Helsinki. The study was approved by the Medical 
Research Ethics Committees United (Mec-U) in Nieuwegein, the 
Netherlands (NTR4636).
Vaccination and Blood sampling
All participants received a single dose of the live-attenuated 
varicella zoster vaccination (Zostavax; Sanofi Pasteur MSD), con-
taining not less than 19,400 PFU. The vaccine was subcutaneously 
administered. A blood sample was taken from all participants 
before the vaccination. Post-vaccination, blood samples were 
taken after 14 days, 28 days, and 1 year (Figure 1). Peripheral blood 
mononuclear cells (PBMCs) were isolated at all time points using 
vacutainer cell preparation tubes (CPT) containing sodium citrate 
(BD Biosciences), according to the manufacturer’s instructions 
(23). Plasma samples were collected after initial spinning of the 
CPT tubes and were filtered using a Corning®Costar® Spin® X filter 
(Sigma-Aldrich) and were frozen at −20°C before further use. After 
the initial collection, the PBMCs were washed with RPMI-1640 
medium (Gibco) supplemented with 1% heat inactivated fetal calf 
serum (FCS, Gibco) and 1% penicillin and streptomycin (Lonza). 
PBMCs were counted and frozen in a 90% FCS, 10% DMSO solu-
tion at −135°C until further use. Moreover, pre-vaccination, and 
at 14 and 28  days post-vaccination, an additional blood sample 
was collected in tubes containing lithium heparin (BD) for detailed 
cellular immune phenotyping. Both the vaccinations and blood 
samplings were performed in the evening hours.
Whole Blood immune Phenotyping
The whole blood cellular immune phenotyping was performed 
within 18 h after blood collection. Pre-vaccination, the absolute 
numbers of lymphocytes, monocytes, granulocytes, CD3+ 
T-cells, NK cells, B-cells, and the different B-cell subsets (naïve 
mature, transitional, natural effector, memory B-cells, and 
plasma cells) were determined with a lyse no-wash protocol 
FigUre 1 | Participants flowchart.
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using TruCOUNT tubes (BD). The following antibodies were 
used: CD3(UCHT1)-BV711, CD16(B73.1)-PE, and CD38(HB7)-
APC-H7 (all from BD Biosciences), CD45(GA90)-OC515 
and CD56(C5.9)-PE (both from Cytognos, Salamanca, Spain), 
CD27(M-T271)-BV421 and IgD(IA6-2)-FITC (both from 
BioLegend, San Diego, CA, USA), and CD19(J3-119)-PE-Cy7 
(Beckman Coulter, Fullerton, CA, USA). Moreover, a detailed 
immune phenotyping was performed separately on the whole 
blood pre-vaccination samples using: CD4(RPA-T4)-BV510, 
CD45RA(HI100)-BV605, and CD28(CD28.2)-PerCP-Cy5.5 
(all from BioLegend), CCR7(150503)-PE-CF594, CD8(SK1)-
APC-H7, CD25(2A3)-FITC, TCRgd(11F2)-PE-Cy7, and 
CD127(hIL-7R-M21)-PE (all from BD Biosciences), and 
CXCR5(51505)-APC (R&D Systems, Minneapolis, MN, USA). 
Absolute numbers of T-cell subsets were calculated using the CD3+ 
T-cell numbers from the TruCOUNT analysis. In addition, 14 and 
28 days post-vaccination whole blood TruCOUNT analysis was 
performed using the following antibodies: CD27(M-T271)-BV421, 
CD45RA(HI100)-BV605, IgD(IA6-2)-FITC, CD8(SK1)-FITC, 
CD4(OKT4)-PerCP-Cy5.5 (all BioLegend), CD3(UCHT1)-BV711, 
CD25(2A3)-PE, CCR7(150503)-PE-CF594, TCRgd(11F2)-
PE-Cy7, and CD38(HB7)-APC-H7 (all BD Biosciences), CD45 
(GA90)-OC515 (Cytognos), CD19(J3-119)-PE-Cy7 (Beckman 
Coulter), and CXCR5(51505)-APC (R&D Systems). Gating strategies 
for the different cell subsets were applied as previously described 
(24). An overview of the different markers used to specify the 
different cell populations is given in Table S2 in Supplementary 
Material. Flow cytometric analyses were performed on a 4-laser 
LSR Fortessa (BD Biosciences) using standardized measurement 
settings (25), and data analysis using FacsDiva V8 (BD Biosciences) 
and FlowJo V10 (FlowJo Company, Ashland, OR, USA).
VZV-specific iFnγ and granzyme  
B (grzB) elispot
Multiscreen 96-well ELISpot plates (Merck Millipore) were 
shortly activated with 70% ethanol after which they were thor-
oughly washed with PBS (Tritium Microbiology) and either 
coated with antihuman IFNγ antibody 1-D1K or antihuman 
GrzB GB10 (1 mg/mL; Mabtech). The coated plates were kept 
overnight at 4°C. The next day, the plates were blocked with 
AIM-V medium (ThermoFisher) containing 5% human AB 
serum (Sigma-Aldrich), hereafter called T-cell medium, for at 
least 1 h at 37°C to avoid non-specific binding. The same batch 
of human AB serum was used for all samples to avoid differ-
ences in antigen concentration during T-cell stimulation. After 
a quick thawing of the PBMCs in T-cell medium, PBMCs were 
thoroughly washed and distributed in concentrations of 3 × 105, 
1.5 × 105, and 7.5 × 104 cells/well over the pre-coated IFNγ or 
GrzB plates. The PBMCs were stimulated with the mock (negative 
control), 6 µg/mL VZV-specific purified antigen (VZ10 strain; 
Genway), or 1 µg/mL Staphylococcus aureus enterotoxin B (SEB, 
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positive control) (Sigma-Aldrich), again in a threefold dilution. 
All stimulations were performed in duplicate. All time points 
of one participant were tested on the same ELISpot plate, to 
reduce assay variation. The plates were incubated for 48 h at 37°C 
with 5% CO2. Next, supernatants of the stimulated cells were 
collected and frozen at −80°C. Subsequently, the plates were 
washed thoroughly and incubated for 2  h at 37°C with either 
mouse antihuman IFNγ antibody 7-B6-1 or mouse antihuman 
GrzB antibody GB11 (both Mabtech). After a washing step, a 
mixture containing Extravidin–alkaline (Sigma-Aldrich) was 
added for 1 h at room temperature. Finally, plates were washed 
and spots were developed by addition of a SIGMAFAST™ 
BCIP/NBT (Sigma-Aldrich) solution. After drying, plates 
were scanned with the Epson ELISpot Scanner, and the spots 
were counted with a standardized protocol using the AELVIS 
software. Numbers of VZV-specific IFNγ and GrzB producing 
cells are presented per 106 PBMCs after subtraction of the spots 
in the mock control. Mock controls on average contained 17 
spots/106 PBMCs for IFNγ and 20 spots/106 PBMCs for GrzB. 
An NK-cell depletion experiment (using CD56 magnetic bead 
separation) was performed to estimate the role of NK cells in the 
IFNγ production as measured in the ELISpot assays.
VZV-specific igg and iga
Varicella zoster virus-specific IgG concentrations (IU/mL) at the 
different time points were measured using a bead-based immu-
noassay as described previously (26). VZV IgA concentrations 
(NTU) were measured using an enzyme-linked immunoassay 
(Genway Biotech, Inc., San Diego, CA, USA) according to the 
manufacturer’s instructions.
cMV serology
CMV IgG concentrations were determined in the plasma samples 
using an enzyme-linked immunoassay (ETI-CYTOK-G Plus, 
P002033, DiaSorin, Saluggia, Italy) according to the manufac-
turer’s indications and as described earlier (24).
VZV-specific T cell activation and iFnγ 
Production
Peripheral blood mononuclear cells were thawed as before. 
Thereafter, 106  cells/well were stimulated with mock (negative 
control) or 6 µg/mL VZV-specific purified antigen (VZ10 strain; 
Genway) in a 48-well plate. Moreover, 5 ×  105  cells/well were 
stimulated with 1 µg/mL SEB (positive control) (Sigma-Aldrich). 
The cells were incubated for 72 h at 37°C with 5% CO2. During 
the last 5  h GolgiPlug protein transport inhibitor containing 
Brefeldin A (1,000× dilution, BD) was added to each well. After a 
thorough washing, cells were incubated for 30 min with a mixture 
of Life-Death Zombie Aqua fluorescent dye (BioLegend) and 
surface antibodies in FACS buffer, containing PBS with 0.5% BSA 
and 2 mM EDTA. The following antibodies were used for surface 
staining: CD3(SK7)-PerCP, CD4(RPA-T4)-ACP, CD45RA(L48)-
PE-Cy7, CCR7(3D12)-BV605, CD56(NCAM16.2)-BV711 (all BD), 
CD38(HIT2)-BV786 (BioLegend), CD8(CLBT8/4, H8)- FITC 
(Sanquin), and HLA-DR(LN3)-APCefluor780 (eBiosciences). 
Subsequently, cells were washed with PBS, and permeabilized for 
20 min with cytofix/cytoperm (BD). A perm/wash solution (BD) 
was used to wash the cells. In addition, the cells were stained for 
30  min with IFNγ (25723.11)-PE. After an additional washing 
step, the cells were resuspended in FACS buffer and immediately 
measured on a 4-laser LSR Fortessa (BD), and the data were 
analyzed using FlowJo V10. Frequencies of activated (CD38+ 
HLA-DR+) and CD4+ IFNγ+ (data not shown) VZV-specific 
cells were calculated after subtraction of the mock control.
cytokine Detection in supernatants
After 48 h of PBMC stimulation, IL2, TNFα, IL5, IL13, and IL10 
concentrations in the supernatants were determined as previ-
ously described (27). Samples with concentrations below the 
lower limit of quantification were assigned half the concentration 
of the lowest measurement. Cytokine concentrations in the mock 
controls were subtracted from those in the antigen stimulated 
samples.
statistics
Only data of participants with measurements at all different 
time points were used for analysis. The numbers of VZV-specific 
IFNγ-producing cells, cytokine concentrations, activated cells, 
and the whole blood TruCOUNT responses at all the different 
time points were compared with the Friedman test. Only if this 
test yielded significant outcomes, the Wilcoxon signed rank 
test was applied to determine significant differences between 
two separate time points analyzed. The VZV-specific IgG and 
IgA responses were log-transformed after which the ANOVA 
was used to compare the different time points. Corrections for 
multiple testing were used as indicated under the figures/tables. 
Participants with low and high pre-vaccination immunity were 
compared at all time points by using the Mann–Whitney U test. 
Correlations were determined by the Spearman’s rho correla-
tion test. Geometric means with the 95% confidence intervals 
were indicated in the graphs. The boxplots used in the figures 
are plotted from the min to max values with indication of the 
median. The whole blood absolute cell numbers were compared 
at the different time points between the participants with low 
and high pre-vaccination CMI with the Mann–Whitney U 
test. The geometric means of these groups were normalized to 
z-scores using the geometric means and standard deviation of 
the total group to be presented in the heat maps. GraphPad V7 
and SPSS V22.0 were used.
resUlTs
Participant characteristics
A total of 53 middle-aged adults participated in this study 
(mean age: 57.6; range 50–65; 66% male) (Figure 1). After a pre-
vaccination blood drawing, all participants received the Zostavax 
vaccine. Follow-up blood samples were drawn at 14 days, 28 days, 
and 1 year post-vaccination. Finally, 49 (92.5%) of the participants 
completed the study. Additional participant health characteristics 
are presented in Table S1 in Supplementary Material. Due to 
sample availability, distinct numbers of participant samples were 
used for the various assays (Figure 1).
FigUre 2 | Varicella zoster virus (VZV)-specific cellular and humoral immunity post VZV vaccination in middle-aged adults. (a) VZV-specific IFNγ-producing cell 
responses per 106 peripheral blood mononuclear cells (PBMCs), as measured by ELISpot, at the different time points pre- and post-vaccination (N = 39) after 
subtraction of the values in the mock control. The different time points were compared with the Wilcoxon singed rank test preceded by the Friedman test and 
corrected for multiple comparisons. (B) VZV-specific IgG responses at the different time points pre- and post-vaccination (N = 47). The IgG (IU/mL) concentrations 
were log-transformed to reach the normality distribution and compared with the ANOVA with correction for multiple testing. The dotted lines indicate the 
seropositivity thresholds. In all graphs, the geometric mean values with 95% confidence interval are indicated. *p < 0.05, ***p < 0.001, and ****p < 0.0001.
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robust short-term VZV-specific cellular 
and humoral Vaccine responses in 
Middle-aged adults
Pre-vaccination, highly variable numbers of VZV-specific IFNγ-
producing cells per 106 PBMCs were observed in the circula-
tion of middle-aged adults (geometric mean 53.4 [35.8–79.6]) 
(Figure 2A). These cells significantly increased shortly after vac-
cination (14 days: geometric mean 101.6 [79.0–130.8]; 28 days: 
geometric mean 115.9 [94.5–142.3]) and returned to baseline 
values 1-year post-vaccination (geometric mean 71.5 [55.1–92.8]) 
(Figure  2A). Importantly, we observed a negative correlation 
between pre-vaccination VZV-specific IFNγ-producing cell num-
bers and the fold change of VZV-specific IFNγ-producing cells 
post-vaccination (14 days: rho: −0.669, 28 days: rho: −0.714, and 
1 year: rho: −0.610; all p < 0.0001). We did not observe correla-
tions between the cellular and humoral responses, indicating that 
these responses develop independently (data not shown). A pre-
liminary NK cell depletion experiment indicated that the majority 
of this IFNγ was produced by the T-cells (data not shown).
All participants possessed pre-vaccination IgG antibody 
concentrations above the VZV seropositivity level of 0.26 IU/mL, 
as established by van Lier et al. (16) (geometric mean 2.0 [1.7–2.5]), 
indicative of previous infection with the VZV virus in all 
participants (Figure  2B). These VZV-specific IgG antibodies 
were found significantly increased at days 14 (geometric mean 
12.4 [9.2–17.6]) and 28 (geometric mean 8.2 [6.1–11.1]) post-
vaccination. Similar to the IFNγ T-cell responses, no significantly 
elevated IgG responses were observed 1-year post-vaccination 
(geometric mean 2.5 [1.9–3.1]) (Figure 2B).
long-term enhancement of VZV-specific 
iFnγ-Producing cell numbers in 
Participants with low Pre-Vaccination cMi
Since we observed a negative correlation between the numbers of 
pre-vaccination IFNγ-producing cells and the vaccine-induced 
increase in these cells, we determined whether differential vac-
cine responses were observed in participants with low and high 
numbers of pre-vaccination VZV-specific IFNγ-producing cells 
(Figure 3), hereafter called participants with low and high pre-CMI. 
The median number of pre-vaccination spots was determined, 
and participants below the median were considered to have low 
pre-CMI whereas participants above the median were considered 
to have high pre-CMI. Remarkably, only participants with low 
pre-CMI showed enhancement of the number of IFNγ-producing 
cells post-vaccination, which was maintained up until 1 year (fold 
change 14  days: 2.7, 28  days: 4.3, and 1  year: 2.2) (Figure  3A). 
On the contrary, numbers of IFNγ-producing cells were not 
significantly enhanced post-vaccination in participants with high 
pre-CMI (fold change 14 days: 1.3, 28 days: 1.1, and 1 year: 0.8) 
(Figure 3A). One-year post-vaccination, some of these participants 
even showed trends toward reduced numbers of IFNγ-producing 
cells compared with pre-vaccination. Interestingly, participants 
with low pre-CMI were significantly older than the participants 
with high pre-CMI, even within this small age-range (Figure 3B).
The two groups showed similar VZV-specific IgG concentra-
tions (Figure S1A in Supplementary Material), confirming the 
independence of the VZV-specific IgG and CMI responses. 
Noteworthy, IgA responses significantly differed between the 
two groups, with stronger responses in the participants with low 
pre-CMI (Figure S1B in Supplementary Material).
To enlarge our understanding of the difference in T-cell 
responses between the participant with low and high pre-CMI, 
we compared the production of several cytokines in the cell 
culture supernatants after 48 h of culture. Significant differences 
were found between the two groups in VZV-specific Th1 and 
Th2 cytokines. Post-vaccination, significant enhancement of the 
VZV-specific IL2, TNFα, IL13, and IL5 secretion was observed 
in the low pre-CMI group, whereas no significant responses were 
found in the high pre-CMI group. Noteworthy, no significant 
IL10 and GrzB responses were observed in both groups (Figure 
S2 in Supplementary Material).
FigUre 3 | Varicella zoster virus (VZV)-specific responses in participants with low and high pre-vaccination IFNγ-producing cells. (a) The number of VZV-specific 
IFNγ-producing cells, as measured by ELISpot, in participants with low (white boxplots, N = 19) and high (gray boxplots, N = 20) pre-vaccination IFNγ-producing 
cells. These groups were determined using the median number of pre-vaccination IFNγ-producing cells. Participants in the low pre-vaccination group possessed 
numbers of VZV-specific IFNγ-producing cells below the median, compared with numbers above the median in the high pre-vaccination group. (B) The age 
distribution of participants with low and high pre-vaccination IFNγ-producing cells. All boxplots are plotted from the min to max values with indication of the median. 
The low and high responders were compared with the Mann–Whitney U test. The different time points were compared with the Wilcoxon signed rank test preceded 
by the Friedman Test with correction for multiple testing. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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Overall, our results indicate strong VZV-specific cytokine and 
IgA responses in the circulation of middle-aged adults with low 
pre- VZV-specific CMI, whereas this response was absent in the 
circulation of adults with high pre-CMI. Importantly, a low pre-
CMI was associated with higher age in this group.
Differential responses in VZV-specific 
activated (cD38+ hla-Dr+) T-cells  
Post-Vaccination in Participants with  
low and high Pre-cMi
Subsequently, we investigated the frequencies of VZV-specific 
activated T-cells, both within the CD4 and CD8 T-cell compart-
ment (gating strategy presented in Figure S3 in Supplementary 
Material). Activated cells were based on the double expression of 
HLA-DR and CD38 (gating strategy in Figure S4 in Supplementary 
Material). Activated VZV-specific CD8 CM cells could not be 
detected, due to the low frequencies of these cells in the circula-
tion (28). We observed elevated frequencies of activated VZV-
specific CD4 T-cells at 14 and 28 days post-vaccination, mainly 
consisting of CM, TemRO, and TemRA cells (Figure 4A). After 
1 year, elevated frequencies of activated CD4 CM and TemRO 
cells were still found. The numbers of VZV-specific activated 
CD8 T-cells were significantly enhanced at all time points 
post-vaccination, and mainly consisted of TemRO and TemRA 
cells (Figure  4B). Remarkably, activated VZV-specific cell 
responses were significantly different between the participants 
with low and high pre-CMI (Figures 4C–F). Participants with 
low pre-CMI showed strong enhancement of the activated VZV-
specific CD4 cells (CM, TemRO, and TemRA) and only a small 
enhancement of the CD8 TemRA response (Figures 4C,E). By 
contrast, participants with high pre-CMI showed a CD8 T-cell 
oriented response, with increased frequencies of VZV-specific 
CD8 TemRA cells up until 1 year (Figure 4F). However, 1-year 
post-vaccination, this group also showed some enhancement of 
the VZV-specific CD4 CM T-cells (Figure 4D). Overall, these 
responses suggest differential induction of T-cell responses in 
participants with low and high pre-CMI, with a more CD4 T-cell 
oriented response in participants with low pre-CMI as compared 
with a more CD8 TemRA oriented response in participants with 
high pre-CMI.
Whole Blood lymphocyte subset Kinetics 
Mirror the Differential Vaccine responses 
in Participants with low and high Pre-cMi
Finally, we determined whether the blood leukocyte responses 
were different between participants with low and high pre-
CMI (Figure S5 in Supplementary Material; Figure  5A). 
Pre-vaccination, a significant difference was found in the CD4/
CD8 T-cell ratio between the two groups: participants with low 
pre-CMI in general possessed a CD4/CD8 ratio above 3, whereas 
participants with high pre-CMI showed a ratio below 3. This 
possibly suggests a compositional difference in the immune 
phenotype between participants with low and high pre-CMI. 
Participants with low pre- CMI showed slightly higher numbers 
of CD4 T-cells (mainly naïve cells), whereas participants with high 
pre-CMI showed slightly higher numbers of CD8 T-cells. This dif-
ference in CD4/CD8 T-cell ratio continued to exist at the different 
time points after vaccination (Figures 5A,F). Correspondingly, 
at 14  days post-vaccination, significantly higher numbers of 
circulating CD4 naïve cells, CD4 TemRA cells, B-cells, and naïve 
mature B-cells were found in the participants with low pre-CMI 
(Figures  5A–E). This result indicates differential lymphocyte 
subset kinetics in participants with low and high pre-CMI 14 days 
post-vaccination and therefore suggests that these responses can 
be used as a short-term biomarker to predict the long-term vac-
cine responses in middle-aged adults.
FigUre 4 | Varicella zoster virus (VZV)-specific activated (CD38+ HLA-DR+) T-cells. The VZV-specific frequency of activated T-cells (based on the double 
expression of CD38 and HLA-DR) in the CD4 (a) and CD8 (B) T-cell compartments in the total group of participants (N = 20). The VZV-specific activated CD4 
T-cells in participants with low (c) and high (D) pre-cell-mediated immunity (CMI). The VZV-specific activated CD8 T-cells in participants with low (e) and high (F) 
pre-CMI. The geometric mean values were used in the graphs. The different time points were compared with the pre-vaccination frequencies with the Wilcoxon 
signed rank test preceded by the Friedman test. The stars in the bars indicate significant differences for specific subsets as compared with the pre-vaccination 
levels, whereas the starts above the bars indicate differences in the total CD4+ of CD8+ VZV-specific activated cells as compared with the pre-vaccination time 
point. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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DiscUssiOn
Our study showed that the pre-vaccination VZV-specific cel-
lular immunity highly affects the VZV vaccine-induced immune 
responses in middle-aged adults. Robust long-term increases 
in VZV-specific CMI, here defined as the numbers of IFNγ-
producing cells, were observed post-vaccination in participants 
with low pre-CMI, whereas no significant enhancement was 
observed in participants with high pre-CMI. Participants with 
low pre-CMI mainly showed long-term enhancement of acti-
vated (based on the double expression of CD38 and HLA-DR) 
CD4 T-cells, while participants with high pre-CMI demonstrated 
increased proportions of activated VZV-specific CD8 TemRA 
cells, suggesting exhaustion of the VZV-specific T-cell response. 
Interestingly, the middle-aged participants with low pre-CMI 
were generally older than participants with high pre-CMI and 
had a higher CD4/CD8 T-cell ratio (>3). Based on these find-
ings, we propose that next to age, pre-vaccination VZV-specific 
CMI and a high CD4/CD8 T-cell ratio (>3) are predictive for 
a productive immune response to VZV vaccination at middle 
age. Moreover, whole blood kinetics, as found in the absolute 
numbers of CD4 naïve cells, CD4 TemRA cells, B-cells, and naïve 
mature B-cells 14 days post-vaccination, might be used as a quick 
short-term predictive parameter for the long-term enhancement 
of VZV-specific CMI.
Previously, a large study (N = 22,439) in Northern America 
and Europe estimated the efficacy of the Zostavax vaccination 
at 50–59 years of age to be approximately 70% (29). This efficacy 
sharply declined toward older age groups (10, 19), suggesting 
possible benefits of timely vaccination to boost the VZV-specific 
FigUre 5 | Comparison of leukocyte subset kinetics between adults with low or high pre-cell-mediated immunity (CMI). (a) Comparison of the whole blood 
absolute immune cell numbers between participants with low and high pre-CMI at the pre- as well as 14 and 28 days post-vaccination time points. The absolute cell 
numbers were normalized to z-scores, using the geometric means of the low and high group, respectively. z-Scores ranged from −0.5 to 0.5. The normalized 
z-scores are displayed on a color scale, ranging from blue (geometric means below the geometric mean of the total group) to red (geometric means above the 
geometric mean of the total group). The white color indicates values equal to the group geometric mean. The stronger the deviation from the group geometric mean, 
the darker the color. Comparison of the CD4 naïve cells (B), CD4 TemRA cells (c), B-cells (D), naïve B-cells (e), and the CD4/CD8 ratio (F) TruCOUNT kinetics 
between the participants with low or high pre-vaccination CMI. The groups were compared per subset with the Mann–Whitney U test. *p < 0.05 and **p < 0.01.
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CMI before reaching old age. Since childhood varicella vaccina-
tion has been implemented in the national immunization program 
of several countries across Europe as well as the US, the VZV-
specific epidemiology in these countries significantly differs from 
those not vaccinating against VZV (5, 16, 30). Consequently, the 
immune responses to the Zostavax vaccine in middle-aged adults 
as investigated in countries with childhood VZV vaccination 
should not be directly extrapolated to our study population, in 
which VZV-specific CMI is more frequently boosted by external 
natural virus circulation. Despite these epidemiological differ-
ences, our results show similar short-term enhancement of the 
VZV-specific CMI in the circulation of middle-aged adults as was 
observed previously (31).
Despite high variation in vaccine responses, the differential 
peripheral responses in participants with low and high pre-CMI 
are remarkable and suggest that mainly middle-aged adults 
with low pre-vaccination CMI benefit from additional immu-
nization. Benefits of the vaccination might not be excluded in 
participants with high pre-CMI, since memory immunity locally 
in lymph nodes and tissue could be increased. Interestingly, more 
participants in their early fifties were found in the high pre-CMI 
group, which might indicate regular natural boosting of VZV 
in this age group. As a consequence of waning immunity to 
natural infection in combination with immunosenescence (10), 
the effect of pre-vaccination immunity might be diminished in 
older age groups. Therefore, the optimum age for VZV vaccina-
tion might be better defined by balancing the combined effects 
of pre-vaccination immunity and age. Based on our findings, 
although numbers of participants were low, we speculate that 
VZV vaccination might be beneficial for participants in their six-
ties, when pre-vaccination levels are relatively low and effective 
vaccine responses are obtained.
Remarkably, the long-term enhancement of the terminally dif-
ferentiated CD8 TemRA cells in participants with high pre-CMI 
may suggest exhaustion of the VZV-specific T-cell pool, although 
a possibly beneficial effect on the function of these CD8 TemRA 
cells in prevention of viral replication cannot be excluded. 
Although the exhaustion needs to be confirmed by measurement 
of several exhaustion markers (32), our results might indicate that 
an additional VZV vaccination in participants with already high 
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levels of pre-vaccination VZV-specific CMI may unintentionally 
cause exhaustion of the VZV-specific T-cell pool. This finding 
may be the result of repeatedly stimulation of VZV-specific 
T-cells by frequent natural boosting in these participants. Of 
note, the vaccination did not induce elevated IL10 production 
or elevated numbers of circulating Treg cells in the participants 
with high pre-CMI, suggesting that the vaccine did not affect the 
suppression of the immune response in these participants.
This indication of these potentially large effects of the pre-vac-
cination VZV-specific CMI on the VZV-specific vaccine response 
requires additional investigation to improve our understanding 
of VZV-specific cellular immune responses. Consequently the 
implementation of a vaccination strategy might enhance the 
protection of older adults against herpes zoster disease. Since the 
pre-vaccination immunity in middle-aged adults may be different 
between countries with and without childhood varicella vaccina-
tion, it is of interest to compare the cellular immune responses 
obtained from this study, with that in middle-aged adults from 
a country with high childhood VZV-vaccination coverage. 
Importantly, a herpes zoster adjuvanted subunit vaccine con-
taining the recombinant glycoprotein E is under evaluation for 
registration, after showing an efficacy rate of 97.2% in protection 
against herpes zoster disease of the elderly (20–22). To further 
improve our understanding of factors affecting VZV-specific 
immune responses, it would also be of interest to investigate the 
effects of pre-vaccination immunity on the T-cell responses initi-
ated by this vaccine.
In addition, we are the first reporting an association between 
the CD4/CD8 T-cell ratio and VZV-specific CMI. Interestingly, 
we observed a significantly higher CD4/CD8 T-cell ratio (>3) 
in participants with low pre-vaccination CMI, suggesting a 
difference in the immune phenotype between the two groups. 
Considering the significantly higher age of the participants with 
low pre-CMI in our study population, our results confirm and 
extend the observation of a general increase in the CD4/CD8 
T-cell ratio with advancing age, as previously shown by others 
(33). The higher CD4/CD8 T-cell ratio, above 3, perhaps indicates 
immune competence in participants with low pre-vaccination 
VZV-specific CMI, and thereby predicts which participants are 
eligible for timely VZV vaccination. Larger cohort studies are 
needed to confirm this observation. Of note, we did not observe 
a negative correlation between the numbers of Treg cells or late-
differentiated CD4 T-cells and the VZV vaccine response, as was 
previously found in nursing home elderly (34). This difference 
might be explained by the low number of participants in our 
study.
Our study is limited by the measurement of VZV-specific CMI 
in the circulation only, which is likely to have a different cellular 
composition compared with tissue sites (28, 35). For example, a 
distinct effect of age was found on peripheral T-cells as compared 
with other compartments (35). Specifically, in contrast to an age 
related decrease in VZV-specific CD4 T-cell numbers in the 
circulation, no age related decrease was found in the skin (15). 
In our study, it cannot be excluded that participants with high 
circulatory levels of VZV-specific CMI might show enhancement 
of VZV-specific CD4 T-cells in the skin, and therefore benefit 
more from the vaccination than concluded based on the analysis 
of the peripheral immune response. Moreover, the long-term 
immunogenicity of this study has to be confirmed by additional 
sampling of the participants at older age, years after vaccination, 
in a comparative study with elderly persons who did not receive 
an additional vaccination.
In conclusion, we found long-term beneficial effects of VZV 
(Zostavax) vaccination on the VZV-specific CMI in the circulation 
of middle-aged adults with low pre-vaccination CMI. Moreover, 
age (>60 years) and a high CD4/CD8 T-cell ratio (>3) were found 
predictive for the presence of low VZV-specific pre-CMI. More 
studies in independent cohorts are required to substantiate these 
findings. Our results suggest that in a population with high levels 
of natural VZV boosting, vaccination against herpes zoster is 
more beneficial in the early sixties and thereby adds important 
knowledge for the further development of strategies to prevent 
the high herpes zoster disease burden in the aging population.
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